ATLANTA – Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial in these patients of one such agent – nivolumab – indicate that along with signs of effectiveness, it also produced significant side effects at the dose initially studied. The findings indicate a need for further clinical trials in this group before being considered for off-label use with these patients, Dana-Farber Cancer Institute investigators report.
Results from the investigator-initiated, multicenter study, which were presented at an oral abstract session at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta also include encouraging follow-up data from a trial in which the checkpoint inhibitor ipilimumab produced responses in nearly one-third of patients with relapsed hematologic malignancies after an allogeneic (donor) stem cell transplant.
The trial of nivolumab – which blocks a protein called PD-1 that can blunt the immune system's attack on cancer – was spurred by retrospective studies that showed that the drug could be effective but often produced harsh side effects, including graft-versus-host disease, a disorder in which immune system cells in transplanted tissue attack a patient's healthy cells. The first six patients in the trial received a dose of 1 mg/kg of body weight. While a patient with lymphoma responded well to the treatment, several others experienced adverse side effects, including two who died of complications that were possibly treatment-related. The next eight participants received a 0.5 mg/kg dose, and the occurrence of significant side effects appears to be less so far, researchers report.
"We're now exploring whether this lower dose is safe and efficacious," says the study's lead author, Matthew Davids, MD, MMSc, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute. "Because of toxicity concerns, we emphasize that treating patients with nivolumab post-transplant should be done in the context of a clinical trial, not off-label."
In the ipilimumab trial – results of which were published last year in the New England Journal of Medicine – many of the participants continue to fare well, Davids remarks. The NEJM paper reported that 32 percent of patients treated with a 10 mg/kg dose responded to the drug after relapsing from an allogeneic stem cell transplant, while none of those receiving a 3 kg/mg dose did. At the ASH meeting, researchers will report that of the 22 patients treated at the 10 mg/kg level, nine remain alive and three are free of disease progression a median of 15 months after the trial ended. One of the patients with leukemia cutis remains in complete remission more than three years from initial dosing.
Because of the divergence of results at the 10 and 3 mg/kg levels, investigators have also been testing a mid-range dose of 5 mg/kg to determine if it strikes the right balance of efficacy and safety. In the 15 patients treated at 5 mg/kg, efficacy appeared to be slightly less than at the 10 mg/kg dose, while the toxicities were "fairly equivalent," Davids remarks. These results indicate that 10 mg/kg is probably the optimal dose for this group of patients, he adds.
###
The senior author of the study is Robert J. Soiffer, MD, of Dana-Farber. Co-authors are: Haesook T Kim, PhD, Alexandra Savell, Michael Mazzeo, Vincent T Ho, MD, Corey S. Cutler, MD, MPH, John Koreth, MBBS, DPhil, Edwin Alyea III, MD, Joseph H. Antin, MD, Pavan Bachireddy, MD, Catherine J. Wu, MD, Jerome Ritz, MD, and Philippe Armand, MD, PhD, of Dana-Farber; Nicole R. LeBoeuf, MD, MPH, of Dana-Farber and Brigham and Women's Hospital; Caitlin Costello, MD, of San Diego Moores Cancer Center, University of California; Alex F. Herrera, MD, of City of Hope; Frederick L. Locke, MD, of H. Lee Moffitt Cancer Center and Research Institute; Peter McSweeney, MD, of Colorado Blood Cancer Institute; Rodrigo O. Maegawa, MD, of Eastern Maine Medical Center; David E. Avigan, MD, of Beth Israel Deaconess Medical Center; Yi-Bin Chen, MD, of Massachusetts General Hospital Cancer Center; Howard Streicher, MD, of the National Cancer Institute; Edward D Ball, MD, of University of California, San Diego; and Asad Bashey, MD, PhD, of Georgia, Northside Hospital, Atlanta, Ga.
About Dana-Farber Cancer Institute
From achieving the first remissions in childhood cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report's Best Hospitals for both adult and pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber/Brigham and Women's Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston's Longwood Medical Area.
Dana-Farber is dedicated to a unique 50/50 balance between cancer research and care, and much of the Institute's work is dedicated to translating the results of its discovery into new treatments for patients in Boston, and around the world.
Media Contact
Brendan Monahan
[email protected]
413-537-4063
@DanaFarber
http://www.dfci.harvard.edu
